Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy in advanced ovarian cancer.

Literature DB >> 6371017

Chemotherapy in advanced ovarian cancer.

Abstract

The chemotherapy of advanced ovarian cancer is reviewed. Treatment with single agents results in low remission rates and few complete remissions. The results have been improved with modern combination chemotherapy, which includes cisplatin, although a longer follow up is needed for definite conclusions to be made concerning survival. Toxicity and drug resistance remain important problems. The future prospects of treatment with emphasis on intraperitoneal chemotherapy are discussed.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1984 PMID： 6371017 DOI： 10.1007/bf00399380

Source DB: PubMed Journal: J Cancer Res Clin Oncol ISSN： 0171-5216 Impact factor: 4.553

28 in total

1. Management of ovarian carcinoma. Current concepts and future prospects.

Authors: J S Tobias; C T Griffiths
Journal: N Engl J Med Date: 1976-04-15 Impact factor: 91.245

2. Chemotherapy in gynecologic cancer.

Authors: J P Smith
Journal: Surg Clin North Am Date: 1978-02 Impact factor: 2.741

3. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease.

Authors: J H Edmonson; T R Fleming; D G Decker; G D Malkasian; E O Jorgensen; J A Jefferies; M J Webb; L K Kvols
Journal: Cancer Treat Rep Date: 1979-02

4. JMS, successor to cisplatin in advanced ovarian carcinoma?

Authors: E Wiltshaw; B D Evans; A C Jones; J W Baker; A H Calvert
Journal: Lancet Date: 1983-03-12 Impact factor: 79.321

5. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).

Authors: J Carmo-Pereira; F O Costa; E Henriques; J A Ricardo
Journal: Cancer Date: 1981-11-01 Impact factor: 6.860

6. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer.

Authors: R F Ozols; R C Young; J L Speyer; P H Sugarbaker; R Greene; J Jenkins; C E Myers
Journal: Cancer Res Date: 1982-10 Impact factor: 12.701

7. The role of chemotherapy in the treatment of gynecologic malignancy.

Authors: J G Masterson; J H Nelson
Journal: Am J Obstet Gynecol Date: 1965-12-15 Impact factor: 8.661

8. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycin.

Authors: R C Park; J Blom; P J Disaia; L D Lagasse; J A Blessing
Journal: Cancer Date: 1980-05-15 Impact factor: 6.860

9. Improved chemotherapy for ovarian cancer with cis-diamminedichloroplatinum and adriamycin.

Authors: H W Bruckner; C J Cohen; J D Goldberg; B Kabakow; R C Wallach; G Deppe; E M Greenspan; S B Gusberg; J F Holland
Journal: Cancer Date: 1981-05-01 Impact factor: 6.860

10. Rewiew of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute.

Authors: J P Smith; T G Day
Journal: Am J Obstet Gynecol Date: 1979-12-01 Impact factor: 8.661

1 in total

1. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.

Authors: Waleed M Abuzeid; Xiaoling Jiang; Guoli Shi; Hui Wang; David Paulson; Koji Araki; David Jungreis; James Carney; Bert W O'Malley; Daqing Li
Journal: J Clin Invest Date: 2009-07 Impact factor: 14.808

1 in total